- Report
- June 2025
- 200 Pages
Global
From €2497EUR$2,789USD£2,140GBP
- Report
- June 2025
- 150 Pages
Global
From €2416EUR$2,699USD£2,071GBP
- Report
- August 2024
- 200 Pages
Global
From €4430EUR$4,949USD£3,797GBP
- Report
- May 2023
- 140 Pages
Global
From €4430EUR$4,949USD£3,797GBP
- Report
- January 2025
- 176 Pages
Global
From €7117EUR$7,950USD£6,099GBP
- Report
- June 2024
- 200 Pages
Global
From €7117EUR$7,950USD£6,099GBP
- Report
- February 2024
- 111 Pages
Global
From €4252EUR$4,750USD£3,644GBP
- Report
- May 2024
- 139 Pages
Global
From €2685EUR$2,999USD£2,301GBP
€3580EUR$3,999USD£3,068GBP
- Report
- May 2024
- 138 Pages
Global
From €2685EUR$2,999USD£2,301GBP
€3580EUR$3,999USD£3,068GBP
- Report
- May 2024
- 139 Pages
Global
From €2685EUR$2,999USD£2,301GBP
€3580EUR$3,999USD£3,068GBP
- Report
- May 2024
- 132 Pages
Global
From €2685EUR$2,999USD£2,301GBP
€3580EUR$3,999USD£3,068GBP
- Report
- May 2024
- 131 Pages
Global
From €2685EUR$2,999USD£2,301GBP
€3580EUR$3,999USD£3,068GBP
- Report
- May 2024
- 137 Pages
Global
From €2685EUR$2,999USD£2,301GBP
€3580EUR$3,999USD£3,068GBP
- Report
- May 2024
- 136 Pages
Global
From €2685EUR$2,999USD£2,301GBP
€3580EUR$3,999USD£3,068GBP
- Report
- December 2023
- 140 Pages
Global
From €3984EUR$4,450USD£3,414GBP
- Report
- June 2025
- 275 Pages
Global
From €4472EUR$4,995USD£3,832GBP
- Report
- August 2025
- 150 Pages
Global
From €2829EUR$3,160USD£2,424GBP
€3536EUR$3,950USD£3,030GBP
- Report
- March 2025
- 150 Pages
Global
From €4342EUR$4,850USD£3,721GBP
- Report
- February 2025
- 150 Pages
Global
From €4342EUR$4,850USD£3,721GBP
- Report
- October 2023
- 107 Pages
North America
From €3089EUR$3,450USD£2,647GBP

The Intravenous Immunoglobulin (IVIG) market is a subset of the biotechnology industry that focuses on the production and distribution of immunoglobulin products. IVIG is a blood product derived from the pooled plasma of healthy donors, and is used to treat a variety of conditions, including autoimmune diseases, infections, and immunodeficiencies. IVIG is also used in the prevention of certain infections in immunocompromised patients.
IVIG is produced by a number of companies, including CSL Behring, Grifols, Kedrion, Octapharma, and Biotest. These companies are involved in the production, distribution, and marketing of IVIG products. They also provide support services such as patient education, reimbursement assistance, and clinical trial support. Additionally, some companies are involved in the development of new IVIG products, such as recombinant immunoglobulins and monoclonal antibodies. Show Less Read more